Hematology Reports (Sep 2022)

Medication-Induced Factor V Inhibition in the Setting of Refractory Coagulopathy

  • Brandon Travis Wiggins,
  • Daniel Ramirez,
  • Daniel Taylor,
  • William Reichardt,
  • Alyssa Kipke,
  • Mark Minaudo

DOI
https://doi.org/10.3390/hematolrep14040041
Journal volume & issue
Vol. 14, no. 4
pp. 290 – 293

Abstract

Read online

Liver cirrhosis is commonly associated with coagulopathies, typically demonstrated by elevated prothrombin time, international normalized ratio, and partial thromboplastin time. In the setting of bleeding related to coagulopathies, oftentimes physicians try to reverse coagulopathy through a variety of methods including the use of vitamin K and fresh frozen plasma. Rarely, attempts at reversing coagulopathy are unsuccessful due to severe disease or factor inhibitors. The treatment of acquired factor V inhibitors is primarily performed through immunosuppression and supportive care for the initial bleeding episode. Early detection and treatment of factor V inhibition is challenging in a setting of underlying cirrhosis-related coagulopathy.

Keywords